Ultragenyx Pharmaceutical Inc. (RARE) recently saw its rating downgraded to Neutral by Goldman Sachs analyst Salveen Richter on March 24, 2026. This change is notable, given the company’s current stock price of $18.50, juxtaposed against a price target of $25. Investors will need to reassess their expectations in light of this rating shift amid ongoing market volatility.
Recent Price Action
Over the past week, RARE has experienced a price decline of 8.73%, closing down $1.77 from the previous trading session. The stock has been trading at a significant discount, currently sitting at $18.50, well below its 52-week high of $25.15 and not far above its low of $18.50. With a market capitalization of approximately $1.79 billion and a beta of 0.208, the stock’s low volatility suggests that it tends to move less dramatically than the broader market. However, trading behavior has seen a spike in recent sessions, with a volume of 3,481,100 shares changing hands, surpassing the average volume of 2,881,954 shares.
Historical Performance
Ultragenyx’s stock has struggled in the short and long term, recording a 30-day performance of -31.86% and a quarterly decline of -30.66%. Compounding these difficulties, the stock has plummeted a staggering 44.6% over the past year. This disappointing trajectory can also be attributed to heightened market conditions impacting the biotechnology sector, where investor sentiment appears cautious and selective. Recent trading has exhibited an average weekly volatility of 4.37%, with monthly volatility reaching as high as 5.96%, indicative of a turbulent trading environment.
Earnings Analysis
In its latest earnings report dated November 4, 2025, Ultragenyx reported an actual EPS of -$1.81, falling short of analysts’ expectations, which were pegged at -$1.23. The company’s considerable EPS surprise of 47.15% illustrates the ongoing challenges it faces in achieving profitability, raising concerns about its operational efficiency and overall earnings predictability. Previously, in August 2025, the company reported an EPS of -$1.17, which also missed the estimate of -$1.27. These successive earnings misses indicate a trend that may deter potential investors seeking stability in earnings performance.
Analyst / Consensus View
The consensus sentiment surrounding Ultragenyx remains cautious, encapsulated by 15 total ratings from analysts. Currently, there are 13 Buy ratings and 2 Hold ratings, with no Sell ratings noted. The average price target currently stands at $69.40, with a broad range from a low of $25 to a high of $128. While the robust number of Buy ratings might appear encouraging, the downgrade to Neutral by Goldman Sachs suggests analysts are increasingly apprehensive about the company’s near-term prospects.
Stock Grading or Fundamental View
Ultragenyx holds a Stocks Telegraph grading score of 39, reflecting challenging fundamentals that may raise red flags for investors. This score is a composite indicator derived from various financial health and market analysis metrics, highlighting the company’s struggles and potential vulnerabilities within the current market landscape.
Conclusion
For investors, Ultragenyx Pharmaceutical Inc. presents a mixed case. The stock may still appeal to those with a high-risk tolerance and a long-term growth perspective, particularly given its substantial upside potential based on analyst price targets. However, the recent downgrade to Neutral by Goldman Sachs signals that investors should proceed cautiously, considering the substantial risks associated with the company’s recent underperformance, particularly in earnings. This stock is worth watching but will require a careful assessment of market conditions and the company’s operational progress before making any swift investment decisions.